IMMX
Los Angeles, CA 90064
US
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Rachman Ilya M | P-Purchase | 746 | $6.67 | 2025-12-10 |
| Morris Gabriel S | P-Purchase | 770 | $6.58 | 2025-12-10 |
| Morris Gabriel S | X-InTheMoney | 156,000 | $0.80 | 2025-12-08 |
| Morris Gabriel S | X-InTheMoney | 60,000 | $0.80 | 2025-12-08 |
| CHANG NANCY T | A-Award | 39,643 | $4.33 | 2025-11-21 |